Alkermes plc (ALKS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ALKS Revenue Growth
Revenue Breakdown (FY 2025)
ALKS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ALKS Revenue Analysis (2014–2025)
As of May 8, 2026, Alkermes plc (ALKS) generated trailing twelve-month (TTM) revenue of $1.56 billion, reflecting exceptional growth of +28.2% year-over-year. The most recent quarter (Q1 2026) recorded $392.9 million in revenue, up 2.2% sequentially.
Looking at the longer-term picture, ALKS's 5-year compound annual growth rate (CAGR) stands at +7.3%, indicating steady revenue expansion. The company achieved its highest annual revenue of $1.66 billion in 2023.
Revenue diversification analysis shows ALKS's business is primarily driven by Vivitrol (40%), Aristada And Aristada Initio (31%), and Manufactured Product And Royalty (25%).
When compared to Healthcare sector peers including INVA (+13.6% YoY), SUPN (+16.3% YoY), and ACAD (+9.9% YoY), ALKS has underperformed the peer group in terms of revenue growth. Compare ALKS vs INVA →
ALKS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALKSCurrent | $1.6B | +28.2% | +7.3% | 17.2% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 AXSM | $638M | +63.9% | - | -26.5% | |
 INTR | $14.6B | - | - | 10.9% |
ALKS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.48B | -5.2% | $1.28B | 86.7% | $254.0M | 17.2% |
| 2024 | $1.56B | -6.4% | $1.31B | 84.2% | $420.6M | 27.0% |
| 2023 | $1.66B | +49.6% | $1.41B | 84.8% | $414.1M | 24.9% |
| 2022 | $1.11B | -5.3% | $893.7M | 80.4% | $-6,089,000 | -0.5% |
| 2021 | $1.17B | +13.0% | $976.4M | 83.2% | $97.7M | 8.3% |
| 2020 | $1.04B | -11.3% | $860.4M | 82.8% | $-112,427,000 | -10.8% |
| 2019 | $1.17B | +7.0% | $990.6M | 84.6% | $-175,479,000 | -15.0% |
| 2018 | $1.09B | +21.1% | $917.9M | 83.9% | $-99,128,000 | -9.1% |
| 2017 | $903.4M | +21.1% | $748.6M | 82.9% | $-147,900,000 | -16.4% |
| 2016 | $745.7M | +18.7% | $613.6M | 82.3% | $-208,665,000 | -28.0% |
See ALKS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALKS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALKS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALKS — Frequently Asked Questions
Quick answers to the most common questions about buying ALKS stock.
Is ALKS's revenue growth accelerating or slowing?
ALKS revenue is accelerating at +28.2% year-over-year, exceeding the 5-year CAGR of +7.3%. TTM revenue reached $1.6B. Growth momentum has increased versus prior periods.
What is ALKS's long-term revenue growth rate?
Alkermes plc's 5-year revenue CAGR of +7.3% reflects the sustained expansion pattern. Current YoY growth of +28.2% is above this long-term average.
How is ALKS's revenue distributed by segment?
ALKS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.